BOSTON,Feb. 14,2025-- Bambusa Therapeutics,Inc. (Bambusa),a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders,today announced the successfu
SHENZHEN,China,Feb. 14,2025-- Kexing Biopharm Co.,Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05,Human Interferon α1b Inhalation Solution,
SHANGHAI,Feb. 13,2025-- OneConnect Financial Technology Co.,Ltd ("OneConnect" or the "Company",NYSE: OCFT,HKSE: 6638),a business technology service provider for financial instituti
Hanmi Pharmaceutical Global Business Headquarters Accelerates Expansion into Canadian and US Markets,Strengthening Collaboration with Distribution Partner McKesson
SEOUL,South Korea,Feb. 14,2025-- Bellevue Life Sciences Acquisition Corp. ("BLAC") announced today the approval of each of the proposals presented at the special meeting of its stockholders
RIYADH,Saudi Arabia,Feb. 14,2025-- The AlUla Conference for Emerging Market Economies,organized jointly by the Saudi Ministry of Finance and the International Monetary Fund (IMF),kicks off next week
BANGKOK,Feb. 13,2025-- Webull Securities (Thailand) Co. Ltd. ("Webull Thailand"),the Thai subsidiary of Webull Corporation ("Webull"),a leading global digital investment platform,
02-14 Webull Securities (Thailand) Company Limited
On the first Wednesday of every month since 2005, rain or shine, a determined circle forms outside Osaka Station. Holding portraits of silver-haired women and signs reading "Let us build a society together where peace and human rights prevail, preserving the memory of history," members of a Japanese civil group raise voices that Tokyo has long tried to silence.
On the early morning of May 12, a 5.5-magnitude earthquake struck Lhaze county, Xigaze, Southwest China's Xizang Autonomous Region. The earthquake had a focal depth of 10 kilometers and affected surrounding areas, including Saga county.
Taipei-based biotech company Jyong Biotech Ltd. has leveraged a successful IPO to accelerate the development of MCS-2, a promising treatment for benign prostatic hyperplasia (BPH).